Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Fingolimod, a sphingosine-1-phosphate receptor (S1PR) modulator, was the first oral disease-modifying therapy approved for relapsing forms of multiple sclerosis; it reduces autoreactive lymphocytes' egress from lymphoid tissues by down-regulating S1PRs. Sphingosine-1-phosphate signaling is implicated in a range of physiologic functions, and S1PRs are expressed differentially in various tissues, including the cardiovascular system. Modulation of S1PRs on cardiac cells provides an explanation for the transient effects of fingolimod on heart rate and atrioventricular conduction at initiation of fingolimod therapy, and for the mild but more persistent effects on blood pressure observed in some patients on long-term treatment. This review describes the nontherapeutic actions of fingolimod in the context of sphingosine-1-phosphate signaling in the cardiovascular system, as well as providing a summary of the associated clinical implications useful to physicians considering initiation of fingolimod therapy in patients. A transient reduction in heart rate (mean decrease of 8 beats per minute) and, less commonly, a temporary delay in atrioventricular conduction observed in some patients when initiating fingolimod therapy are both due to activation of S1PR subtype 1 on cardiac myocytes. These effects are a reflection of fingolimod first acting as a full S1PR agonist and thereafter functioning as an S1PR antagonist after down-regulation of S1PR subtype 1 at the cell surface. For most individuals, first-dose effects of fingolimod are asymptomatic, but all patients need to be monitored for at least 6 hours after the first dose, in accordance with the label recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Self-citationFingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Self-citationMechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
Pham, T. H. M., Baluk, P., Xu, Y., Grigorova, I., Bankovich, A. J., Pappu, R., Coughlin, S. R., McDonald, D. M., Schwab, S. R., & Cyster, J. G. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091619 · Cited by 444
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
Billich, A., Bornancin, F., Dévay, P., Mechtcheriakova, D., Urtz, N., & Baumruker, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307687200 · Cited by 433
Sanna, M. G., Wang, S.-K., Gonzalez-Cabrera, P. J., Don, A., Marsolais, D., Matheu, M. P., Wei, S. H., Parker, I., Jo, E., Cheng, W.-C., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio804 · Cited by 406
Cited by
Takata, F., Nakagawa, S., Matsumoto, J., & Dohgu, S. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661838 · Cited by 651
Sphingosine 1-phosphate: Lipid signaling in pathology and therapy
Cartier, A., & Hla, T. (2019) · Science · doi:10.1126/science.aar5551 · Cited by 613
Self-citationDrug-Induced Arrhythmias: A Scientific Statement From the American Heart Association
Tisdale, J. E., Chung, M. K., Campbell, K. B., Hammadah, M., Joglar, J. A., Leclerc, J., Rajagopalan, B., & On behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing (2020) · Circulation · doi:10.1161/cir.0000000000000905 · Cited by 399
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
McGinley, M. P., & Cohen, J. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00244-0 · Cited by 310
Sphingosine 1-phosphate and inflammation
Obinata, H., & Hla, T. (2019) · International Immunology · doi:10.1093/intimm/dxz037 · Cited by 268
Self-citationFinding a way out: S1P signaling and immune cell migration
Baeyens, A. A. L., & Schwab, S. R. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-081519-083952 · Cited by 123
Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways
Kim, S. M., Roy, S. G., Chen, B., Nguyen, T. M., McMonigle, R. J., McCracken, A. N., Zhang, Y., Kofuji, S., Hou, J., Selwan, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87148 · Cited by 77
“org Volume 126 Number 11 November 2016 despite their activity in vitro and in animal models (21, 22).”
BackgroundNg, H. S., Zhu, F., Zhao, Y., Yao, S., Lu, X., Ekuma, O., Evans, C., Fisk, J. D., Marrie, R. A., & Tremlett, H. (2024) · Neurology · doi:10.1212/wnl.0000000000208006 · Cited by 31
Transport and inhibition of the sphingosine-1-phosphate exporter SPNS2
(2025) · doi:10.1038/s41467-025-55942-7 · Cited by 15
Metadata
- Authors
- Camm, J., Hla, T., Bakshi, R., & Brinkmann, V.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 168
- Issue
- 5
- Pages
- 632-644
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W1981879391
- Cited by
- 210
- References
- 6
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.